Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.70
+0.11 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
47
48
Next >
New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
December 30, 2022
A study in China shows that a remdesivir analog, dubbed VV116, is as effective as Pfizer Inc's (NYSE: PFE) oral COVID-19 pill.
Via
Benzinga
This New Drug Could Be Gilead Sciences' Growth Catalyst
December 29, 2022
Another potential blockbuster drug in Gilead's hands.
Via
The Motley Fool
3 High-Yielding Dividend Stocks That Could See Hikes in January
December 29, 2022
These stocks all pay more than 3% in dividends.
Via
The Motley Fool
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
December 28, 2022
Via
Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
December 28, 2022
Gilead will try to win approval for what is now GS-1811, while Jounce develops other immunotherapy drugs. JNCE stock is soaring.
Via
InvestorPlace
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors' Attention Today
December 27, 2022
U.S. markets opened lower on Tuesday in a truncated week after rising bond yields dragged major growth stocks and indices.
Via
Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
December 27, 2022
Via
Benzinga
Could Gilead (GILD) Continue On The Bull Run?
December 17, 2022
Using the Wycoff trading method, we see that Gilead Sciences, Inc (GILD) will likely continue its bullish momentum.
Via
Talk Markets
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
December 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
3 Stocks That Could Soar in a Santa Claus Rally
December 25, 2022
These stocks are primed for a holiday surge.
Via
The Motley Fool
Gilead Sciences to Present at Upcoming Investor Conference
December 23, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
December 23, 2022
The market uptrend is under pressure.
Via
Investor's Business Daily
3 Nasdaq Stocks That Are Up 25% in 3 Months
December 23, 2022
Should you jump on the bandwagon and buy these surging stocks?
Via
The Motley Fool
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
FDA Approves Gilead's New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients
December 22, 2022
Via
Benzinga
Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot
December 22, 2022
The twice-yearly option is attractive for patients that don't get adequate treatment from pills alone.
Via
Investor's Business Daily
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Analyzing Gilead Sciences's Short Interest
December 21, 2022
Gilead Sciences's (NASDAQ:GILD) short percent of float has fallen 15.15% since its last report. The company recently reported that it has 17.56 million shares sold short, which is 1.4% of all regular...
Via
Benzinga
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
December 20, 2022
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock.
Via
InvestorPlace
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
Via
Benzinga
Why Is Gilead Sciences Stock Sliding Tuesday?
December 20, 2022
Gilead Sciences Inc (NASDAQ: GILD) shares are trading lower Tuesday after the company reported results from its Phase 2 non-small
Via
Benzinga
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
December 20, 2022
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche.
Via
Investor's Business Daily
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients
December 20, 2022
Via
Benzinga
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
December 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tuesday Talk: Where is Santa?
December 20, 2022
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
Via
Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
December 19, 2022
From
Arcus Biosciences
Via
Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
December 13, 2022
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.
Via
Investor's Business Daily
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.